The East Is Ready: A New Axis Of Pharmaceutical Innovation
By Fangning Zhang, Anirudh Roy Popli, and Jay Park
For much of the past two decades, the geography of pharmaceutical innovation was relatively stable. Discovery and capital clustered in hubs such as Boston, San Diego, and Basel. Asia played an important but supporting role in manufacturing, clinical trial recruitment, and selective licensing.
That balance is shifting. Recent McKinsey research shows Asia is now a primary engine of global pharmaceutical innovation. In 2024, the region contributed more than 85 percent of global growth in innovative drug pipelines and generated nearly two-thirds of biotech patents worldwide, more than five times Europe’s contribution. Asia now accounts for 43 percent of the global innovation pipeline, up from 28 percent in 2020.
This shift is not simply incremental growth. It reflects sustained investment in scientific talent, translational infrastructure, and increasingly sophisticated capital markets. As a larger share of early discovery, development speed, and capital formation moves to the region, so does influence over where value is created and how innovation ecosystems evolve.
China is responsible for nearly a third of the global innovation pipeline. Discovery-to-clinical timelines are up to 70 percent faster than global averages, and late-stage development trials, aided by concentrated patient pools, well-resourced sites, and mature clinical capabilities, can run two to five times faster than in the United States and Europe. At the same time, China is not just moving faster; it is expanding beyond a historical focus on oncology into immunology, neurology, and metabolic diseases, broadening both its scientific scope and clinical depth.
This momentum extends beyond China. South Korea has secured multibillion-dollar licensing deals, including GSK’s $2.5 billion agreement with ABL Bio to develop drugs for neurodegenerative diseases and LigaChem’s $1.7 billion partnership with J&J Innovative Medicine. Japan brings deep in R&D and commercialization experience, supporting global franchises such as Daiichi Sankyo in antibody-drug conjugates, a form of targeted cancer therapies, and Eisai in Alzheimer’s disease. Singapore has emerged as a Southeast Asia hub for early-stage biopharma development. And India, long a leader in pharmaceutical manufacturing scale, is moving beyond generics into biosimilars, injectables, and innovative drug discovery. That evolution is increasingly visible in global dealmaking, including AbbVie’s $1.9 billion agreement with Glenmark for an oncology asset developed in India, signaling growing confidence in the country’s research capabilities as well as its manufacturing strength.
This shift is unfolding amid significant complexity. Geopolitical tensions continue to shape cross-border capital flows and technology transfer. Regulatory systems differ in speed, transparency, and data requirements. Capital markets on both sides have experienced volatility, and intellectual property protection, while strengthening across much of Asia, remains a concern for some multinational companies. Yet even against this backdrop, capital, talent, and innovation activity continue to concentrate in the region.
The shift toward Asia is not cyclical. It reflects structural advantages across talent, infrastructure, capital deployment, and execution speed. Artificial intelligence is reinforcing this momentum. AI-enabled high-throughput screening, in silico lead optimization, and data-driven indication expansion are accelerating core R&D activities. Regions that combine scale, data access, clinical infrastructure, and execution speed are positioned to benefit most, further strengthening Asia’s role in shaping the next phase of biopharmaceutical innovation.
For global pharmaceutical companies, this changes the strategic calculus. Many have historically approached Asia primarily as a source of cost-efficient outsourcing or opportunistic in-licensing. That posture is increasingly untenable. Asian companies offer differentiated capabilities across discovery, development speed, and clinical execution. The conversation has shifted from whether to access Asia to how to embed its innovation capabilities into global R&D models. Positioning, not just presence, will determine who captures the next wave of growth.
These considerations are no longer theoretical; they are increasingly reflected in how leading companies deploy capital and structure partnerships. In 2025, for example, AstraZeneca acquired Belgium-based EsoBiotech, whose most advanced treatment was originally based on technology developed by China’s Pregene Biopharma. The acquisition was primarily about accelerating timelines: by tapping Pregene’s infrastructure and execution speed, AstraZeneca was able to fast-track early-stage trials of its in vivo cell therapy program.
While Asia is home to myriad stand-alone opportunities, the opportunity is bigger than just acquisitions or partnerships. Asia’s capabilities increasingly form an integrated regional value chain: a therapy developed in China, for example, might tap into South Korea’s large molecule manufacturing. Or it may be possible to link early-stage work in China with India’s strength in formulation. Companies that combine these strengths can unlock speed, cost advantages, and scientific breadth that are difficult to replicate within a single geography.
For pharmaceutical companies globally, the path forward is clear. Integrating regional capabilities into core operating models is no longer optional. Companies that succeed will help shape where and how the next wave of innovation is generated. Those that do not, risk ceding strategic influence over discovery, development speed, capital formation and long-term value creation.
About The Authors:
Fangning Zhang, Partner, is a leader in the Life Sciences practice in Greater China and for the last 17 years has served pharmaceutical and medtech companies on topics related to business strategy, innovation, business development and M&A, organization, and transformation. She began her career with McKinsey in the New Jersey office before moving to Shanghai in 2010.
Jay Park, Partner, is a core leader of McKinsey’s Life Sciences practice in Asia. Since joining McKinsey, he has extensively engaged in life sciences projects in Japan, South Korea, and the United States. In recent years, he has advised pharmaceutical and biotech companies, focusing on their innovation strategies, globalization strategies, and corporate-wide transformations.
Anirudh Roy Popli is a Partner with McKinsey & Co. He co-leads the Life sciences practice in India as well as the Life Sciences Innovation/R&D service line in Asia.